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1. Introduction 
The human genome sequence project has made a great impact on medical science and drug 
discovery (Collins et al., 2003). The rapid progress of genome sequencing technologies 
enables us to study personal genome sequences with reasonable costs (Mitchelson, 2007). It 
is now widely believed that personal genome information will be one of the most important 
biomedical contributions to personalized medicine, that is, medical and health care based on 
individual genetics (Angrist, 2007). Personalized medicine has opened the doors to new and 
emerging technologies in genome drug discovery, including pharmacogenetics, 
pharmacokinetics, and pharmacodynamics, to name but a few. Pharmacogenetics 
investigates genetic effects in drug metabolic enzymes and drug transporters for drug 
efficacy (Pirmohamed, 2011). Pharmacokinetics and dynamics (PKPD) focus on the area 
under plasma concentration time curve (AUC) of drugs, one of the important indices to 
check the drug effects in the human body, especially for preventing adverse side effects 
(Gabrielsson et al., 2009). 
Although both pharmacogenetics and PKPD have revealed the association between genetic 
mutations and drug efficacy, their accomplishments are not sufficient yet for clinical 
purpose, especially with respect to prediction performance (Pirmohamed, 2011). Why are 
the associations between genetic mutations and drug efficacy so vague? Why can 
pharmacokinetic models not predict drug metabolism correctly? Why does model 
parameter fitting not work well in prediction tasks? These questions motivated us to initiate 
the study of personalized pharmacokinetics, the opposite side of conventional 
pharmacokinetics, that is, population pharmacokinetics (Willmann et al., 1994). 
The basic approach to personalized pharmacokinetics is the breakdown of the 
pharmacokinetic problem into the dynamics of molecular interactions between drug 
metabolic enzymes and drug metabolites. In this approach, the molecular interactions and 
the drug metabolites are represented by ontologies. The key concepts of pharmacokinetics, 
such as drug metabolic pathways and drug-drug interactions are also represented by the 
aggregation of molecular interactions and the conflicts of molecular interactions on the same 
enzymes, respectively. The severities of drug-drug interactions are measured by 
mathematical simulation models represented by ordinal differential equations 
corresponding to molecular interactions. 
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Personalized pharmacokinetics is one of the in silico studies and trial simulations but differs 
from population pharmacokinetics in the following sense. The objective is the analysis of the 
genetic traits of an individual patient rather than the average and distribution of these traits 
in the patient population. A pharmacokinetic model is constructed from the knowledge base 
of drug metabolic reactions according to an individual regimen, not from a statistical 
analysis or machine learning applied to population data. The model is used for the 
estimation of parameter distribution reproducing the observed clinical data from the 
viewpoint of an inverse problem. 
In order to achieve the above goals, we have developed a prototype system for personalized 
pharmacokinetics, which consists of the Drug Interaction Ontology, the inference programs 
for drug-drug interaction detection and generation of metabolic pathways and models, and 
the pharmacokinetic numerical simulation engine with virtual patient population 
convergence facility. The Drug Interaction Ontology is a kind of knowledge representation 
with regards to drug metabolism (Yoshikawa et al., 2004). It consists of two vocabulary 
hierarchies in terms of process and continuants like the SNAP-SPAN ontology, that is, a 
combination of a purely spatial ontology supporting snapshot views of the world at 
successive instants of time and a purely spatiotemporal ontology of change and process 
(Grenon&Smith, 2004a). The process vocabulary hierarchy defines the dynamics of drug 
metabolism. The continuant vocabulary hierarchy defines categories of bio-chemical 
molecules related to drug metabolism. A drug metabolism knowledge base is developed on 
the Drug Interaction Ontology as a collection of anonymous objects representing drug 
metabolic reactions and their aggregation, that is, drug metabolic pathways. The Drug 
Interaction Ontology is represented by OWL-DL. However, the logic programming 
language Prolog is used for drug-drug interaction detection and generation of metabolic 
pathways and pharmacokinetic numerical simulation models.  
The inference programs compensate the lack of knowledge in the form of anonymous 
objects in the drug metabolic pathway knowledge base. The inference programs 
dynamically generate anonymous instances, such as drug metabolic pathways and detect 
the occurrences of drug-drug interactions, when a patient’s regimens are given. The 
automatic generation of drug metabolic pathways is indispensable for multiple drug 
regimens since the total number of drug metabolic pathways becomes the number of all 
possible combinations of drugs, which are meaningless to be provided in the drug metabolic 
knowledge base in advance. Instead, the knowledge base consists of a collection of primitive 
drug metabolic reactions and inference programs to generate drug metabolic pathways of 
multiple-drug regimens. The drug-drug interaction detector detects the occurrences of drug-
drug interactions in the generated drug metabolic pathways and then dynamically adds the 
occurrences as hypothetical assertions in the drug metabolic pathway knowledge base, 
mapping the assertions on process and continuant vocabulary hierarchies. The mapping 
gives useful background information to validate the assertions. In addition, the mapping is 
also helpful to generate a pharmacokinetic numerical simulation model when choosing an 
appropriate mathematical equation corresponding to competitive and non-competitive 
enzymatic inhibition. 
The virtual patient population convergence is a concept for solving an inverse problem. The 
objective is to estimate multiple sets of parameters reproducing the personal clinical datum 
of an individual patient. The inverse problem approach is very different from conventional 
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population pharmacokinetics that tries to estimate the average and diversity of a patient 
population. In our approach, only the clinical data of an individual patient are necessary. 
This enables us to analyze an “outlier” of the population. We strongly believe that the 
analysis of such outliers is more important than the analysis of average behaviors for 
practical personalized pharmacokinetics. 
In order to demonstrate the effectiveness of our approach, we applied the prototype system 
to the pharmacokinetic studies of anti-cancer drug irinotecan with a whole body 
pharmacokinetic model with regards to the hepatic and renal excretions of five major 
irinotecan metabolites: CPT-11 (irinotecan), APC1, NPC2, SN-38 (active metabolite of 
irinotecan), and SN-38G (SN-38glucuronide). Firstly, we investigated how ketoconazole 
affects the irinotecan metabolite blood concentrations with the pharmacokinetic model in 
(Arikuma et al., 2008). Ketoconazole inhibits CYP3A4, one of the drug metabolic enzymes of 
irinotecan. The numerical simulation analysis revealed an interesting behavior of the drug 
metabolism, which is difficult to expect from pathway-level analysis. Then, we investigated 
how the UGT1A1*28/*28 mutation affects SN-38 blood concentration in the Arikuma model. 
UGT1A1*28/*28, also known as Gilbert’s syndrome, is one of the important mutations that 
may cause severe side-effects when using irinotecan (Tukey et al, 2002). The simulation 
result suggests how the expression level of UGT1A1 affects the metabolite concentration of 
SN-38. Lastly, we investigated kinetic parameters reproducing a bile-duct cancer patient 
who showed a metabolite excretion profile that was completely different from other cancer 
patients. This is a typical example of an inverse problem. The result indicates that the 
analysis of the solution space of the inverse problem is a key to understanding the peculiar 
behavior of an outlier like this bile-duct cancer patient. 
The organization of this chapter is as follows. Firstly, we describe our motivation and 
background of studying personal pharmacokinetics in Section 2. Sections 3 describes the 
prototype system which consists of the Drug Interaction Ontology, inference programs for 
pathway (model) generation and drug-drug interaction detection, and numerical 
simulation engine with the facility of virtual patient population convergence. Section 4 
introduces three case studies of irinotecan pharmacokinetics, drug-drug interaction of 
irinotecan and ketoconazole, mutation analysis of drug metabolic enzyme UGT1A1, and 
an inverse problem analysis of a bile-duct cancer patient with an external bile drain. 
Section 5 discusses the controversial points of this work. Finally, section 6 gives the 
conclusions of our study. 
2. Personalized pharmacokinetics 
The role of in silico prediction of drug interactions at the pathway level is becoming more 
and more important for personalized medicine. Multiple-drug regimens exemplify the need 
for the computer-assisted prediction of drug interactions, which may be different from one 
patient to another. Multiple-drug regimens are commonly prescribed for elderly patients 
suffering from more than one disease. However, these regimens sometimes cause 
unexpectedly severe side effects because of the drug interactions or individual differences 
concerning response to the drugs (Okuda et al., 1998). Therefore, the prediction of drug 
                                                 
1 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin 
2 7-ethyl-10-(4-amino-1-piperidino) carbonyloxycamptothecin 
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interactions for preventing the side effects is an important issue for these regimens. On the 
other hand, the information useful for in silico drug interaction prediction has increased very 
rapidly in recent years. Technological innovations in genomic sciences have produced an 
enormous amount of bio-molecular information including sequences, structures, and 
pathways. In order to integrate the bio-molecular information, ontologies are attracting a lot 
of attention (Baker & Cheung, 2007; Konagaya, 2006a, 2006b). In addition, pharmacokinetics 
modeling and simulation are emerging, promising techniques to understand the dynamic 
behavior of drug metabolic pathways (Tsukamoto et al., 2001;Vossen et al., 2007). To 
develop personalized pharmacokinetics that can deal with individual drug administration 
including multiple-drug regimens by integrating the above information and techniques, the 
following issues must be solved: 
- Context dependency of drug-metabolic pathways, 
- Treatment of multi-scale events, 
- Quantitative evaluation of interactions, 
- Automatic generation of simulation models, 
- Inverse problem solving of an outlier, 
and so on. 
Drug-metabolic pathways do not exist a priori. They strongly depend on contexts and 
situations including the administration route, single nucleotide polymorphism (SNP) of 
drug-response genes, and the administration of multiple drugs and foods. Therefore, a 
dynamic reconstruction of drug metabolic pathways from primitive molecular events is 
necessary for drug interaction prediction at the pathway level. Such a reconstruction 
requires the formal definition of molecular events and the relations among them, i.e., the 
Drug Interaction Ontology (DIO) (Yoshikawa et al, 2004). 
Pathways triggered by drug administration consist of multi-scale events: from the molecular 
level to the body level, ranging from nanoseconds to hours or days in terms of drug 
response. For example, drug administration and drug excretion are body-level events, while 
drug transport and enzymatic reactions are molecular-level events. A comprehensive view 
from the molecular level to the body level is necessary in order to understand multi-scale 
events. 
Quantitative evaluation plays an essential role to estimate the degree of side effects caused 
by drug interactions. More than one drug interaction may occur in drug-metabolic 
pathways from the qualitative reasoning viewpoint. However, not all drug interactions 
cause side effects because of differences in binding affinity and molecular population. 
Quantitative simulation models with an in silico drug interaction prediction system must be 
incorporated to discriminate serious drug interactions from negligible ones. It should also be 
noted that the total drug metabolism depends on not only kinetic parameters but also 
physiological parameters such as organ volumes and blood flows. The incorporation of 
kinetic and physiological parameters is necessary for a realistic simulation model to 
recapture experimental data.  
The automatic generation of mathematical models is necessary to avoid a combinatorial 
problem of drug metabolic pathways caused by multi-drug regimens and the occurrences of 
drug-drug interactions. On-demand automatic generation of simulation models also 
liberates modelers from the tedious editing of complex differential equations.  
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In the case of pharmacokinetics, we often encounter an outlier caused by a peculiar patient 
who shows different clinical data from other patients. In order to analyze such an outlier, 
inverse problem solving is necessary. Since most pharmacokinetic models are 
underdetermined, that is, they have dozens of parameters which are difficult to determine 
by biological experiments or clinical observation, the solution space of inverse problems 
becomes a multiple-set or a manifold. Finding multiple sets that reproduce the observed 
clinical data on a pharmacokinetic model is one of the major challenges in numerical 
simulation. We solved this issue by restricting the search space within physiologically 
reasonable ranges, and by utilizing intelligent sampling techniques with a Markov-Chain 
Monte Carlo (MCMC) method and Support Vector Machine (SVM) method in the prototype 
system.   
3. Prototype system 
The prototype system for personalized pharmacokinetics consists of the Drug Interaction 
Ontology, the inference programs for drug-drug interaction detection and generation of 
metabolic pathways and models, and the pharmacokinetic numerical simulation engine 
with virtual patient population convergence facility (Fig.1). 
 
Fig. 1. The Organization of the Prototype System 
The prototype system consists of the Drug Interaction Ontology, inference programs and 
simulation engine. A drug metabolic pathway is represented by an anonymous object whose 
compounds are linked to terms in the continuant hierarchy, and whose reactions are linked 
to terms in the process hierarchy. The inference programs generate a metabolic pathway by 
aggregating primitive reaction objects. After detecting the occurrences of the drug-drug 
interaction, the generated pathway is translated to a model, that is, a list of ordinal 
differential equations. The simulation engine estimates a virtual patient population 
reproducing an observed clinical datum by means of solving an inverse problem with the 
equations. 
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3.1 Drug Interaction Ontology (DIO) 
The ontological approach in knowledge base design is adopted for resource sharing and the 
semantic description of molecular events and pathways. Ontology is necessary to define 
molecular events and pathways in a form that can be shared among computers and human 
beings. This enables the full use of powerful computational intelligence for dynamic 
pathway reconstruction in a way that human intelligence can follow and understand. 
Ontology is also important for establishing interoperability among web resources and 
thereby to make use of the latest drug reaction information published in the semantic web 
(Baker&Cheung, 2007; Berners-Lee&Hendler, 2001). Public biological ontologies, especially 
in the field of chemical biology, are now dramatically increasing and have a great potential 
to develop sustainable knowledge bases for molecular reaction and pathways 
(Ceusters&Smith, 2010). 
The Drug Interaction Ontology is designed to share the knowledge of drug-drug interaction 
in both machine and human understandable form. The controlled vocabularies of the Drug 
Interaction Ontology consist of "process" (Fig. 2) and "continuant" (Fig. 3) as proposed in 
Basic Formal Ontology (BFO) (Grenon et al., 2004b). Molecular events are asserted in the 
knowledge base referring the terms of the controlled vocabularies. A drug metabolic 
pathway is represented by the aggregation of molecular events. This is because an infinite 
number of terms or classes are required to express all combinations of molecular events. We 
avoid this problem by treating pathways as anonymous objects deduced from prototype 
molecular event objects rather than treating them as instances of pathway classes. 
 
Fig. 2. A Part of Process Vocabulary Hierarchy 
Process vocabulary hierarchy defines the terminology of metabolic reactions from molecular 
level to body level. Note that each term in the process hierarchy may have more than two 
kinds of anonymous reaction objects or their aggregations categorized into the same term. 
This facility enables to avoid combinatorial expansion of terms to deal with aggregation of 
anonymous reaction objects. 
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Fig. 3. A Part of Continuant Vocabulary Hierarchy 
Continuant vocabulary hierarchy defines the terminology of compounds, cells and organs 
which contribute the human body. The terminologies imported from reference ontologies 
are prefixed by identifies such as “fma” and “umls” for the Foundational Model of Anatomy 
and Unified Medical Language System, respectively. 
Ontology provides not only a class hierarchy of controlled vocabulary but also property and 
relations among terms useful for inferences. The inferences may include qualitative 
reasoning and numerical simulation, i.e., pathway generation, drug-drug interaction 
detection, differential equation generation, and numerical simulation as well as reasoning 
on OWL-DL. Obtained results such as drug interaction candidates can be dynamically 
mapped on the ontology as hypothetical assertions. This approach is attractive since it can 
use ontology as background knowledge to interpret the inference results. 
The Drug Interaction Ontology (DIO) was written in OWL-DL; the controlled vocabularies 
of process and continuant were implemented as OWL class hierarchy, and part of attributes, 
including molecules and organs, were implemented as OWL instances. The molecular event 
objects were represented by OWL instances and OWL properties. The ontology referred to 
other taxonomies and ontologies for well-established vocabularies of biochemical terms, 
anatomical entities, and properties. This enabled the reduction of our ontology construction 
cost and to concentrate our efforts on the information specific to drug interaction. 
3.2 Automatic generation of drug metabolic pathways 
The drug metabolic pathway, due to its dynamic nature, is difficult to define a priori in the 
manner as seen in bio-molecular metabolic pathways in the Kyoto Encyclopedia of Genes 
and Genomics (KEGG) (Kanehisa&Goto, 2000). Therefore, modularization is necessary for 
the dynamic reconstruction of pathways that depend on dose conditions. Careful selection 
of primitive modules is the key to ensuring the soundness of pathway reconstruction. 
Molecular events, such as molecular transport and enzymatic reactions, are well-formed 
primitive modules for this purpose. In this chapter, we refer to the primitive modules as 
"molecular events", and the aggregation of molecular events as "pathways". To avoid 
redundant pathway branch constructions, which are non-essential for the target drug 
interactions, we adopt causality-based modularization in which each molecular event is 
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defined by the unique relationship between key molecules before and after the event. The 
triadic relationship <trigger, situator, resultant> is one such causality that can be commonly 
found in molecular reactions (Yoshikawa et al., 2004). For example, in case of enzymatic 
reactions, substrates, enzymes and other products correspond to trigger, situator, and 
resultant, respectively. In the case of molecular transport, extra (intra) cellular molecules, 
transporters, and intra (extra) cellular molecules correspond to the participants of the triadic 
relation, respectively. The triadic relationship can be applicable to higher level events like 
drug dosage and drug excretion, as long as its causality is unique and clear. Figure 4 shows 
a simple example of pathway reconstruction with two primitive molecular events: an 
enzymatic reaction in which carboxylesterase (CE) metabolizes irinotecan into SN-38 (7-
ethyl-10-hydroxycamptothecin) in the liver, and molecular transport in which SN-38 in the 
liver is transported to the bile by MRP2 (Multidrug resistance-associated protein 2). Two 
molecular events are connected at the resultant of the enzymatic reaction and the trigger of 
the molecular transport for passing SN-38 in the liver (SN-38@liver) to the bile. 
 
Fig. 4. Reconstruction of Drug Metabolic Pathway from Primitive Reactions 
Each primitive metabolic reaction is represented by a triplet of <trigger, situator, resultant>. 
Metabolic pathway is constructed by aggregation of primitive reactions where a resultant 
becomes a trigger of the consecutive reaction as like SN-38 for CE and MRP2. Each 
compound has location information indicated by the @ symbol to deal with migration 
process across organs such as MRP2. 
3.3 Automatic generation of drug metabolic pharmacokinetic models 
In order to incorporate a quantitative numerical simulation into the prototype system, the 
following two aspects are considered: a methodology for the automatic conversion from a 
generated pathway to a quantitative simulation model, and a methodology to solve an 
inverse problem, that is, virtual patient population convergence. These two methodologies 
enable us to apply the prototype system to the in silico prediction of individual drug 
interactions for multiple-drug regimens, assuming that kinetic parameters and the initial 
enzyme concentration are roughly estimated by individual genetic variations and health 
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indices of bio-markers. A simulation model is automatically translated from a drug 
metabolic pathway generated by the inference programs. The generated pathway is 
converted to an intermediate model by merging organs and molecular events, respectively, 
to fit a given simulation model such as a compartment model. Then, a list of ordinal 
differential equations for the simulation model is generated from the intermediate model by 
converting the merged events to mathematical expressions.  
Figure 5 shows a simulation model automatically generated for the co-administration of 
irinotecan and ketoconazole. The organs and tissues are integrated into 8 compartments, i.e., 
blood (including rapidly equilibrating tissues: artery, heart, kidneys, lung, and veins), liver, 
GI (gastrointestinal consists of the large intestine, small intestine, portal vein, and stomach), 


























































Fig. 5. Generated Pathway Model for Irinotecan and Ketoconazole Co-administration 
The model consists of 8 compartments: Blood, Liver, Adipose, Gut-Intestine (GI), GI-Lumen, 
Urine, Bile-Lumen, and Net. Irinotecan is injected directly into the Blood compartment in 
the way of intravenous drip. The Blood compartment plays a central role to circulate drug 
metabolites to other compartments. The GI-Lumen and the GI compartments are provided 
for the oral administration of ketoconazole. The Urine and the Bile-Lumen compartments 
are provided for the renal and hepatic excretions of irinotecan metabolites. Drug metabolic 
reactions are occurred in the Liver compartment. The Adipose and the Net compartments 
are provided for the difference of blood circulation speeds of organs. 
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and urine. Michaelis-Menten equations are used for all enzymatic reactions. A competitive 
Michaelis-Menten inhibition model is used for this simulation as used for midazolam and 
ketoconazole inhibition by (Chien et al., 2006). In order to increase the predictive 
performance, a simplified pathway is used for the generation of simulation models from the 
viewpoint of the trade-off between model complexity and data availability. For example, in 
the case of irinotecan and ketoconazole metabolisms, reabsorption through small intestine 
and reactions concerning albumin are omitted due to the lack of information.  
The generated simulation models and pharmacokinetic moment parameter values are 
mapped onto the Drug Interaction Ontology as hypothetical assertions. The simulation 
models are asserted as aggregations of objects representing terms and parameters in 
differential equations. Those objects having references to the components of the pathway 
objects from which the simulation models are generated. The moment parameter values are 
asserted with the drug interaction objects and the corresponding simulation model for the 
further analysis. See (Arikuma et al., 2008) for the details of ontology, mathematical models, 
and their implementations of irinotecan and ketoconazole drug metabolic pathways. 
3.4 Virtual patient population convergence 
Virtual patient population convergence is a concept to find a partial set of virtual patients 
reproducing an observed clinical datum in some error range with regards to a given 
mathematical model by means of iteration of numerical simulation and population selection 
starting from an initial virtual patient population (Fig.6). In general, the solution space of a 
mathematical model, that is, the virtual patient population reproducing an observed clinical 
data on the model, might be infinite. In addition, there is a trade-off between the virtual 
patient sampling time and the precision of the virtual patient population converged to the 
observed clinical data. Therefore, some kind of criteria with regards to the “goodness” of 
convergence for virtual patient population must be defined. 
 
Fig. 6. Schematic View of Virtual Patient Population Convergence  
Virtual Patient Population Convergence estimates a virtual population mapping onto the 
neighbourhood of the target by iterating simulation and re-sampling of virtual patients. 
Intelligent sampling method is required to reduce total simulation costs for the convergence. 
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First of all, each virtual patient should hold reasonable parameters from the viewpoints of 
physiology and pharmacokinetics. This requires that the search space should be restricted 
within or around the initial virtual patient population. Virtual patients with unrealistic 
parameters must be eliminated during the convergent process. Note that the search space is 
still wide enough since some pharmacokinetic parameters such as maximum velocity 
(Vmax) of enzymatic reaction range over the order of 10 to the power of 5 or 6 in an initial 
population. 
Next, care must be taken for the handling of errors in the observed clinical data. The clinical 
data may have five or more percent of errors. Therefore, it is more important to preserve the 
diversity of virtual population as much as possible rather than to find a precise virtual 
patient reproducing the observed clinical data.  
Lastly, convergence speed does matter. A mathematical model usually has dozens of 
unknown parameters. The virtual patient population convergence tries to find a “good” 
population by iteration of simulation and sampling by assigning new values to the 
unknown parameters of a virtual patient. Random sampling does not work well for this case 
due to the large search space. Sophisticated sampling algorithms must be developed to solve 
practical inverse problems of pharmacokinetics. 
For example, Arikuma’s irinotecan pharmacokinetic model has 61 input parameters and 10 
output parameters with regards to irinotecan metabolism (Arikuma et al., 2008). Suppose 
that the goal of convergence is to find a virtual population whose error is within the ranges 
of 1/10 of the target output on each output parameter. This may correspond to finding a 
rare event occurring one-tenth for each ten parameters, that is, once every 10 billion if we 
assume a uniform distribution. 
Intelligent sampling such as Gibbs sampling and Markov Chain Monte Carlo (MCMC) 
methods are helpful to avoid redundant sampling. We accelerated the sampling 
performance of the MCMC method by using a support vector machine (SVM) to estimate 
the boundary of virtual patients reproducing the neighbour of the target output values. 
Intelligent sampling with regards to the boundary is much faster than the sampling with 
simulation, although some candidates inside the boundary may fall out of the 
neighbourhood of the target data due to the non-linear behaviour of simulation model.  
4. Case studies 
In order to demonstrate the effectiveness of the prototype system, we applied it to the 
irinotecan pharmacokinetic studies including multi-drug administration of irinotecan and 
ketokonazole, mutation effects of UGT1A1*28/*28 and the hepatic and renal excretion 
analysis of the bile-duct cancer patient with an external bile-drain. Irinotecan is an anti-
cancer drug that is commonly used for colon and breast cancers (Mathijssen et al., 2001). 
Irinotecan is a prodrug of SN-38, anti-neoplastic topoisomerase I inhibitor, and is bio-
activated by carboxyl esterase (CE). About 60% of irinotecan is excreted as unchanged drug 
from bile and kidney (Slatter et al., 2000). Irinotecan is also metabolized by CYP3A4 to form 
APC and NPC. NPC is further metabolized by CE to form SN-38. SN-38 undergoes 
glucuronate conjugation by UGT1A1 to form the inactive glucronide, SN-38G.  
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Ketoconazole (KCZ) is an anti-fungal drug and a well-known inhibitor of CYP3A4. 
Ketoconazole undergoes extensive metabolism in the liver to form several metabolites 
(Whitehouse et al., 1994). About 2 to 4% of urinary radioactivity represents unchanged drug 
(Heel et al., 1982). It has been reported that the inhibition of CYP3A4 by ketoconazole 
influences the metabolism of irinotecan, which results in a 6% SN-38 increase (Kehrer et al., 
2002). In addition, it is known that the mutations on UGT1A1, UGT1A1*28/*28 which 
decreases the expression of UGT1A1 enzyme down to 30%, has a strong relationship with 
some side effects of irinotecan (Sai et al., 2004; Ando et al., 2000). 
Slatter et al. reported that the bile cancer patient with an external bile-drain showed 
completely different renal and hepatic metabolite excretion profiles from other cancer 
patients in their pharmacokinetic studies (Slatter et al., 2000). Why was the bile cancer 
patient so different from the other cancer patients? Which parameter caused the difference? 
This case is a typical example that requires personalized pharmacokinetics, in other words, 
the analysis of an outlier. 
4.1 Drug-drug Interaction between Irinotecan and ketoconazole 
The pathways of intravenously administered irinotecan and orally administered 
ketoconazole were inferred as aggregation of molecular events by the Pathway Object 
Constructor. The generated object included a metabolic pathway where irinotecan and its 
derivatives circulate through the veins, liver, bile, intestines, and portal vein, namely, the  
 
Fig. 7. Detected Drug-Drug Interactions mapped onto the Drug Interaction Ontology 
Four drug-drug interaction events are detected on the irinotecan and ketoconazole 
coadministrated metabolic pathway, which are mapped onto the Drug Interaction Ontology. 
Seven primitive reactions are involved in the events. Three of them and the rest are mapped 
onto the oxidation process and the drug_binding process, respectively. 
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enterohepatic circulation, and are excreted through the kidneys or through the bile. These 
generated pathways were consistent with in vivo studies (Mathijssen et al., 2001). 
Interactions between intravenously administered irinotecan and orally administered 
ketoconazole were detected and asserted by the Drug Interaction Detector. The detected 
drug interactions and the hypothetic assertions are shown in Fig. 7. The assertion contains 
four drug interactions; two of them concern "drug binding reaction" to albumin in veins 
(ddi2) and arteries (ddi3), and the rest of them concern "oxidation" by CYP3A4 (ddi0 and 
ddi1). The detected drug interaction concerning CYP3A4 (ddi0 and ddi1) has been 
confirmed by the literature on in vivo studies (Kehrer et al., 2002). 
We evaluated the effects of drug interactions concerning CYP3A4 quantitatively with 
numerical simulations. Intravenous drip infusion (125 mg/m2, 90 min) was assumed for 
irinotecan, and oral administration (200 mg) was assumed for ketoconazole. Two 
simulations were performed: sole administration of irinotecan for a patient having 
UGT1A1*1/*1 (wild type) and co-administration of irinotecan and ketoconazole for a 
patient having UGT1A1*1/*1 (wild type). Fig. 8 (a) and (b) show the simulated 
concentration/time profiles of irinotecan, SN-38, APC, NPC, SN-38G in blood for the 
simulation of sole administration of irinotecan and co-administration of irinotecan and  
 
Fig. 8. Simulation Results of Time Course Concentration:  
(a) Sole Irinotecan Administration (wild type) 
(b)Multiple-administration of Irinotecan and Ketoconazole (wilde type) 
(c) Sole Irinotecan Administration (UGT1A1*28/*28 mutation) 
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ketoconazole. By the ketoconazole administration, the area under the plasma concentration-
time curve (AUC) of APC and NPC were decreased to 48.1% and 35.3%, respectively. The 
AUC of SN-38 was increased only to 108% by the ketoconazole administration. Similarly, 
the maximum drug concentration (Cmax) of APC and NPC were decreased to 25.6% and 
20.2%, respectively, whereas the Cmax of SN-38 was increased to 105% by the ketoconazole 
administration. This implies that effects of co-administration of ketoconazole and irinotecan 
are mild for the blood concentration of SN-38 in spite of inhibition of CYP3A4 in the drug 
metabolic pathway. 
4.2 Effects of UGT1A*28/*28 mutation 
It is reported that a patient with UGT1A1*28/*28 mutation decreased the expression of 
UGT1A1 down to 30% of patients with UGT1A1*1/*1 (wild type) in average. According to 
our quantitative evaluation with numerical simulation, the patient with UGT1A1*28/*28 
mutation significantly increased the AUC and Cmax of SN-38: the AUC was increased to 
208% and the Cmax was increased to 165% (Fig. 8 (c)). This implies that patients with 
UGT1A1*28/*28 may suffer severe side effects when the doses are the same as those for 
patients with UGT1A1*1/*1. These results agree with previously published experimental 
papers (Kehrer et al., 2002; Sai et al., 2004; Ando et al., 2000).  
4.3 Analysis of a bile-duct cancer patient with an external bile-drain 
In their pharmacokinetic study, Slatter et al. reported that the bile-duct cancer patient with 
an external bile-drain showed completely different renal and hepatic metabolite excretion 
profiles from other cancer patients (Slatter et al., 2000). Since the bile-duct cancer patient 
excreted her bile acid through an external bile-drain, it is possible to observe the hepatic 
clearances directly. As seen in Table 1, the ratio of hepatic and renal metabolite excretions is 
completely different between the bile-duct cancer patient and the other cancer patients; the 
ratio is almost the same for the bile-duct cancer patient while the ratio is 1-to-2 for the other 
cancer patients. Slatter et al. explained that the difference might result from the inhibition of 
canalicular multiple organic anion transporter (cMOAT/MRP2/ABCC2) in the bile-duct 
cancer patient. This is one of the typical examples that require the analysis of an outlier, that 
is, personalized pharmacokinetics. 












CPT-11 21.8 24.7 22.4(5.5) 32.3(4.5) 
APC 7.7 5.6 2.2(1.5) 8.3(3.0) 
SN-38G 12.0 2.7 3.0(0.8) 0.3(0.2) 
SN-38 0.9 3.2 0.4(0.1) 8.2(2.5) 
NPC 0.09 0.62 0.1(0.1) 1.4(0.9) 
Total 45.8 43.4 30.2(6.6) 62.0(7.6) 
Table 1. Percentages of Administrated Dose Excreted from Urine and Faeces in the Bile-duct 
Cancer Patient and the Average of Other Cancer Patients summarized from the 
Pharmacokinetic Study reported by (Slatter et al. 2000). 
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Bile acid excretion and faeces excretion are added for the bile-duct cancer patient. The total 
percentage does not recover all administrated dose due to the experimental limitations and 
drug metabolisms other than the CPT-11, APC, SN-38G, SN-38, and NPC. 
Arikuma et al. have developed an irinotecan metabolic pathway model with five major 
irinotecan metabolites: CPT-11(irinotecan), APC, NPC, SN-38 and SN-38G (Arikuma et al., 
2008). Since those components occupy about 90 percent of irinotecan metabolites, it is 
sufficient to consider the dynamics of blood concentration of the five compounds with renal 
and hepatic excretions as a pharmacokinetic model. The challenge for personalized 
pharmacokinetics is whether Arikuma’s model can reproduce the bile-duct patient data or not.  
Figure 9 shows the set of virtual patients whose simulation results fall into the 
neighbourhood of the bile-duct patient within a 5 percent error margin in hepatic and renal 
excretions of CPT-11, APC, NPC, SN-38 and SN-38G after virtual patient population 
convergence. The distribution shows clear dependency in hepatic and renal excretions in 
CPT-11, but no such dependencies in other components.  
 
Fig. 9. Distribution of Virtual Patient Population reproducing the Hepatic and Renal 
Irinotecan Metabolite Excretions of the Bile-duct Cancer Patient 
Horizontal and vertical axes represent hepatic and renal excretions, respectively. The centre 
of each square in the graphs is the target excretion of the bile-duct cancer patient estimated 
from the pharmacokinetic study reported by Slatter et al. 2000. Each dot represents a virtual 
patient whoes hepatic and renal excretions are within the five percent error ranges on the 
pharmacokinetic simulation. 
In the case of an undetermined inverse problem, what we can obtain is just a multi-set of 
solution candidates. We cannot determine the true solution because of the lack of 
conditions. However, it would be reasonable to expect that the solution candidates may 
have common properties reproducing the target data in the inverse problem. Figure 10 
shows the averages and distributions of the hepatic clearances converged to metabolic 
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excretions of the bile-duct cancer patient and the averages of other cancer patients. 
Intriguingly, there is a clear down-regulation in APC, SN-38, and SN-38G between the two, 
suggesting coincidence with the pharmacogenetic study of ABCC2 (Innocenti et al., 2009). 
 
Fig. 10. Comparison of the bile-duct cancer patient and the other cancer patients with 
regards to the Average and Distribution of Hepatic Clearances in Virtual Patient Population 
after Convergence 
Horizontal axis represents estimated hepatic clearances in numerical simulation (unit 
l/h/m2). 
5. Discussion 
Our study on personalized pharmacokinetics is still in its infancy. Ontology and 
mathematical simulation are powerful information technologies but need more research for 
practical use, especially from the viewpoints of knowledge representation and unknown 
parameter estimation. In this section, we discuss these issues. 
5.1 Knowledge representation and inference 
It is widely known that there is a trade-off between the amount of knowledge base and 
deepness of inference in knowledge representation, that is, shallow inference on huge 
knowledge base and deep inference on small knowledge base. Both approaches have their 
own merits. Therefore, it is important to choose the right size of knowledge base and the 
right level of inference in knowledge representation. 
As for biomedical ontologies, OWL becomes one of de facto standards, especially in the 
world of Semantic Web, the network of knowledge with inference in the Internet (Timizi et 
al, 2011). It adopts a unique representation form of knowledge with UNICODE, URI 
(Uniform Resource Identifier) and RDF (Resource Description Form), and provides an 
inference engine, named reasoning based on description logic (Zhang et al., 2006). 
We adopted OWL-DL for the implementation of the Drug Interaction Ontology to make it 
consistent with reference ontologies such as Foundation of Model of Anatomy (FMA) 
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(Rosse&Mejino, 2003) and Unified Medical Language System (UMLS) (Bodenreider, 2004). 
The reference ontologies enable us to focus on the development of a control vocabulary 
specific to pharmacokinetics while allowing the usage of general technical terms as defined 
in the reference ontologies. In addition, the OWL reasoner helps indentify unsatisfiable 
classes and consistency checking in Ontology (Zhang et al., 2006). 
However, it is apparent that OWL-DL is not suitable for the detection of drug-drug 
interactions and the generation of metabolic pathways. We strongly believe that inference 
programs on ontology should not be restricted to the level of reasoning. Therefore, we 
developed our inference programs in Prolog while using OWL-DL for consistency checking 
of the Drug Interaction Ontology. 
The inference programs may infer new assertions that cannot be deduced from the original 
ontology in reasoning. In such a case, it is impossible for computers to validate the 
assertions automatically. In order to compensate for the lack of automatic validation, we 
introduced hypothetical links that map the assertions on the Drug Interaction Ontology. The 
hypothetical links give useful background information for human beings to validate the 
assertions. For example, in the case of the drug-drug interaction detection of irinotecan and 
ketoconazole, four drug-drug interaction events (from ddi0 to ddi3 in Fig. 6) were found by 
our inference program. Mapping the events onto the process vocabulary hierarchy enables 
us to interpret ddi0 and ddi1 as enzymatic inhibition of CYP3A4 while ddi2 and ddi3 are 
binding confliction on albumin. 
5.2 Distribution estimation 
Mathematical models expressed by ordinal differential equations define the mapping from 
parameter space to accumulation data space when integrating the equations from zero to a 
specific time point. The mapping is mostly nonlinear, and multiple sets of parameters may 
reproduce the same accumulation data. The virtual patient population convergence is a 
technique to estimate the distribution of virtual patients reproducing the same or similar 
accumulation data when the initial population is given in an inverse problem.  
From the viewpoint of parameter distribution estimation algorithms, the virtual patient 
population convergence raises several issues such as initial population dependency and 
early convergence to local minima as well as convergence performance. As for the 
convergence performance, we have developed a very fast deterministic algorithm, the 
details of which will be published elsewhere (Aoki et al., 2011). Further studies should be 
carried out for the rest. 
Another important issue related to the virtual patient population convergence is the 
interpretation of solution space, that is, the obtained population after convergence. 
Mathematical models often have parameter-parameter dependencies that compensate for 
the effect of certain parameters by means of adjusting other parameters to reproduce the 
same output (Azuma et al., 2007). This suggests focusing on the analysis of parameter 
diversities of the solution space, rather than the analysis of an individual virtual patient of 
the solution space. In case of the bile-duct cancer patient of irinotecan pharmacokinetics, the 
virtual patients in solution space falls into specific parameter ranges on hepatic clearances. 
However, care must be taken when the ranges seem to be strange from the viewpoint of 
biology and medical science. In such a case, the specific ranges may result from a deficiency 
of the model to explain the behavior of the outlier.  
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The effectiveness of personalized pharmacokinetic is demonstrated by the in silico analysis 
of an irinotecan pharmacokinetic study with the Drug Interaction Ontology and automatic 
drug metabolic pathway generation followed by numerical simulation.  
As for drug-drug interaction detection, the prototype system detected four drug interactions 
for an irinotecan plus ketoconazole regimen. Two of them concerned cytochrome p450 
(CYP3A4) and were consistent with known drug interactions. The numerical simulation 
indicates that the effect of the drug-drug interactions is mild for the increase of SN-38 blood 
concentration although APC and NPC blood concentrations are reduced considerably.  
We then quantitatively examined the effect of genetic variation UGT1A1*28/*28 using 
numerical simulations. The genetic variation on UGT1A1 showed a two-fold increase of SN- 
38's AUC as suggested by the literature (Gagne et al., 2002). 
Finally, we analyzed the pharmacokinetic parameters reproducing the bile-duct cancer 
patient with an external bile-drain in terms of hepatic and renal metabolic excretions of 
CPT-11, APC, NPC, SN-38 and SN-38G. The obtained virtual patients suggests that the 
difference of hepatic clearances in APC, SN-38 and SN-38G may be the major reason that 
causes the clinical differences between the bile-duct cancer patient and the other cancer 
patients in irinotecan pharmacokinetics. 
7. Acknowledgments  
The author expresses his thanks to Mr. Takeshi Arikuma and Mr. Takashi Watanabe for the 
development of the prototype system including the Drug Interaction Ontology; the 
inference programs of automatic generation of pathways and models, and the detection of 
drug-drug interactions, the numerical simulation engine with virtual patient population 
convergence facility.  
8. References  
Aoki, Y.; Hayami, K.; Hans, DS. & Konagaya, A. (2011). Cluster Newton Method for 
Sampling Multiple Solutions of an Underdetermined Inverse Problem: Parameter 
Identification for Pharmacokinetics, NII Technical Report (NII-2011-002E) 
Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; 
Shimokata, K. & Hasegawa, Y. (2000). Polymorphisms of UDP-Glucuronosy 
ltransferase Gene and Irinotecan Toxicity: A Pharmacogenetic Analysis, Cancer 
Research, Vol. 60, pp.6921-6926 
Angrist, M. (2007). Here is a Human Being at the Dawn of Personal Genomics, Harper 
Arikuma, T.; Yoshikawa, S.; Watanabe, K.; Matsumura, K. & Konagaya, A. (2008). Drug 
Interaction Prediction using Ontology-driven Hypothetical Assertion Framework 
for Pathway Generation followed by Numerical Simulation, BMC Bioinformatics, 
vol. 9 (Suppl 6), S11 
Azuma, R.; Umetsu, R.; Ohki, S.; Konishi, F.; Yoshikawa, S., Matsumura, K. & Konagaya, A. 
(2007). Discovering Dynamic Characteristics of Biochemical Pathways using 
Geometric Patterns among Parameter-Parameter Dependencies in Differential 
Equations, New Generation Computing, Vol.25, pp.425-441 
www.intechopen.com
 Towards an In Silico Approach to Personalized Pharmacokinetics 
 
281 
Baker, CJ. & Cheung, KH. (2007) Semantic Web: Revolutionizing Knowledge Discovery in the Life 
Sciences, Springer 
Berners-Lee, T. & Hendler J. (2001). The Semantic Web, Nature, Vol.410, No.6832, pp.1023-
1024 
Bodenreider, O. (2004). The Unified Medical Language System (UMLS): Integrating 
Biomedical Terminology, Nucleic Acids Research, Vol.32, D267-D270 
Ceusters,W. & Smith,B. (2010). A Unified Framework for Biomedical Terminologies and 
Ontologies, Studies in Health Technology and Informatics, Vol.160(Pt 2),pp.1050-1054 
Chien, JY. ; Lucksiri, A.: Charles, S.; Ernest, I.; Gorski, JC.; Wrighton, SA. & Hall SD. (2006). 
Stochastic Prediction of CYP3A-Mediated Inhibition of Midazolam Clearance by 
Ketoconazole, Drug Metab Dispos, Vol.34, No.7, pp.1208-1219 
Collins, FS.; Green, ED.; Guttmacher, AE. & Guyer, MS. (2003). A Vision for the Future of 
Genomic Research, Nature, vol. 422, pp.835-847 
Gabrielsson, J.; Dolgos, H.; Gillberg, PG.; Bredberg, U.; Benthem, B. & Duker, G. (2009). 
Early Integration of Pharmacokinetic and Dynamic Reasoning is Essential for 
Optimal Development of Lead Compounds: Strategic Consideration, Drug 
Discovery Today, Vol.14, No.7, pp.358-372 
Gagne, JF.; Montminy, V.; Belanger, P.; Journault, K.; Gaucher, G. & Guillemette C. (2002). 
Common Human UGT1A Polymorphisms and the Altered Metabolism of 
Irinotecan Active Metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), Molecular 
Pharmacology, Vol.62, No.3, pp.608-617 
Grenon, P. & Smith, B. (2004a). SNAP and SPAN: Towards Dynamic Spatial Ontology. 
Spatial Cognition and Computation, Vol.1, pp.69-103 
Grenon, P.; Smith, B. & Goldberg, L. (2004b). Biodynamic Ontology:Applying BFO in the 
Biomedical Domain, In: Ontologies in Medicine Amsterdam, IOS Press, pp.20-38 
Heel, R.; Brogden, RA.; Carmine, PM.; Speight, T. & Avery, G. (1982). Ketoconazole: A 
review of its Therapeutic Efficacy in Superficial and Systemic Funfal Infections, 
Drugs, Vol.23, pp.1-36 
Innocenti,F.; Kroetz, DL.; Schuetz, E.; Dolan, ME.; Ramirez, J.; Relling, M.; Chen,P.; Das,S.; 
Rosner,GL. & Ratain,MJ. (2009). Comprehensive Pharmacogenetic Analysis of 
Irinotecan Neutropenia and Pharmacokinetics, Journal of Clinical Oncology, 
Vol.27, No.16, pp.2601-2614 
Kanehisa, M. & Goto, S. (2000). KEGG: Kyoto Encyclopedia of Genes and Genomes, Nucleic 
Acids Research, Vol.28, pp.27-30 
Kehrer, DF.; Mathijssen, RH.; Verweij, J; de Bruijn, P. & Sparreboom, A. (2002). Modulation 
of Irinotecan Metabolism by Ketoconazole, Journal of Clinical Oncology, Vol.20, 
No.14, pp.3122-3129 
Konagaya, A. (2006a). OBIGrid: Towards the Ba for Sharing Resources, Services and 
Knowledge for Bioinformatics, Proceedings of the 4th International Workshop on 
Biomedical Computations on the Grid (BioGrid'06), Singapore 
Konagaya, A. (2006b). Trends in Life Science Grid: from Computing Grid to Knowledge 
Grid, BMC Bioinformatics, Vol.7 (Suppl 5):S10 
Mathijssen, RHJ.; van Alphen, RJ.; Verweij ,J.; Loos, WJ.; Nooter, K.; Stoter, G. & 
Sparreboom, A. (2001). Clinical Pharmacokinetics and Metabolism of Irinotecan 
(CPT-11), Clinical Cancer Research, Vol.7, pp.2182-2194 
Mitchelson, KR. (Ed.) (2007). New High Throughput Technologies for DNA Sequencing and 
Genomics, Elsevier, UK 
www.intechopen.com
 Molecular Interactions 
 
282 
Okuda, H.; Ogura, K.; Kato, A.; Takubo, H. & Watanabe, T. (1998). A Possible Mechanism of 
Eighteen Patient Deaths Caused by Interactions of Sorivudine, a New Antiviral Drug, 
with Oral 5-fluorouracil Prodrugs. J Pharmacol Exp Ther, Vol. 287, No.2, pp.791-799  
Pirmohamed, M. (2011). Pharmacogenetics: past, present and future, Drug Discovery Today, 
Aug. 22nd,Epub ahead of print 
Rosse, C. & Mejino, JLV. (2003). A Reference Ontology for Biomedical Informatics: the 
Foundational Model of Anatomy, Journal of Biomedical Informatics, Vol.36, 
pp.478-500 
Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Katori, N.; Jinno, H.; Hasegawa, R.; Kaniwa, N.; 
Sawada, J.; Komamura, K., Ueno, K.; Kamakura, S.; Kitakaze, M., Kitamura, Y.; 
Kamatani, N.; Minami, H; Ohtsu, A; Shirao, K.; Yoshida, T. & Saijo, N. (2004). 
UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased 
Serum Bilirubin in Irinotecanadministered Japanese Patients with Cancer. Clin 
Pharmacol, Ther, Vol. 75, pp.501-515 
Slatter, JG.; Schaaf, LJ.; Sams, JP.; Feenstra, KL.; Johnson, MG.; Bombardt, PA.; Cathcart, KS; 
Verburg, MT.; Pearson, LK.; Compton, LD.; Miller, LL.; Baker, DS.; Pesheck, CV.; 
Raymond, S. & Lord, I. (2000). Pharmacokinetics, Metabolism, and Excretion of 
Irinotecan (CPT-11) Following I.V. Infusion of [14C]CPT-11 in Cancer Patients, 
Drug Metabolism and Disposition, Vol.28, No.4, pp.423-433 
Timizi,SH.; Aitken,S.; Moreira, DA.; Mungall, C.; Seueda, J.; Shah, NH. & Miranker, DP. 
(2011). Mapping between the OBO and OWL Ontology Languages, Journal of 
Biomedical Semantics 2011, Vol.2 (Suppl 1):S3 
Tsukamoto, Y.; Kato Y; Ura. M.; Horii, I.; Ishitsuka, H.; Kusuhara, H. & Sugiyama, Y. (2001). 
A Physiologically based Pharmacokinetic Analysis of Capecitabine, a Triple 
Prodrug of 5-FU, in Humans, the Mechanism for Tumor-selective Accumulation of 
5-FU, Pharm Res, Vol.18, No.8, pp.1190-1202 
Tukey, RH.; Strassburg, CP. & Mackenzie, PI. (2002). Pharmacogenomics of Human UDP-
Glucuronosyltransferases and Irinotecan Toxicity, Molecular Pharmacology, Vol.62, 
No.3, pp.446-450 
Vossen, M.; Sevestre, M.; Niederalt. C.; Jang, IJ.; Willmann. S. & Edginton, AN. (2007). 
Dynamically Simulating the Interaction of Midazolam and the CYP3A4 Inhibitor 
Itraconazole using Individual Coupled Whole-Body Physiologically-based 
Pharmacokinetic (WBPBPK) Models. Theoretical Biology and Medical Modelling, Vol. 
4, No. 13 
Whitehouse, LW.; Menzies, A.; Dawson, B.; Cyr, TD.; By AW.; Black, DB. & Zamecnik, J. 
(1994). Mouse Hepatic Metabolites of Ketoconazole: Isolation and Structure 
Elucidation, J Pharm Biomed Anal 1994, Vol. 2, No.11, pp.1425-1441 
Willmann, S.; Hohn, K.; Edginton, A.; Sevestre, M.; Solodenko, J.; Weiss, W.; Lippert, J. & 
Schmitt ,W. (2007). Development of a Physiology-based Whole-Body Population 
Model for Assessing the Influence of Individual Variability on the 
Pharmacokinetics of Drugs, Pharmacokinet Pharmacodyn, Vol. 34, No.3, pp.401-431 
Yoshikawa, S.; Kenji, S. & Konagaya, A. (2004). Drug Interaction Ontology (DIO) for 
Inferences of Possible Drug-Drug Interactions, Medinfo, Vol.11, pp.454-458 
Zhang, S.; Bodenreider, O. & Golbreich, C. (2006). Experiences in Reasoning with the 




Edited by Prof. Aurelia Meghea
ISBN 978-953-51-0079-9
Hard cover, 400 pages
Publisher InTech
Published online 29, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
In a classical approach materials science is mainly dealing with interatomic interactions within molecules,
without paying much interest on weak intermolecular interactions. However, the variety of structures actually is
the result of weak ordering because of noncovalent interactions. Indeed, for self-assembly to be possible in
soft materials, it is evident that forces between molecules must be much weaker than covalent bonds between
the atoms of a molecule. The weak intermolecular interactions responsible for molecular ordering in soft
materials include hydrogen bonds, coordination bonds in ligands and complexes, ionic and dipolar interactions,
van der Waals forces, and hydrophobic interactions. Recent evolutions in nanosciences and nanotechnologies
provide strong arguments to support the opportunity and importance of the topics approached in this book, the
fundamental and applicative aspects related to molecular interactions being of large interest in both research
and innovative environments. We expect this book to have a strong impact at various education and research
training levels, for young and experienced researchers from both academia and industry.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Akihiko Konagaya (2012). Towards an In Silico Approach to Personalized Pharmacokinetics, Molecular
Interactions, Prof. Aurelia Meghea (Ed.), ISBN: 978-953-51-0079-9, InTech, Available from:
http://www.intechopen.com/books/molecular-interactions/towards-an-in-silico-approach-to-personalized-
pharmacokinetics
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
